TESARO, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public, Subsidiary
- Established
- 2010-03-01
- Employees
- 715
- Market Cap
- -
- Website
- http://tesarobio.com
Clinical Trials
120
Active:85
Completed:21
Trial Phases
4 Phases
Phase 1:74
Phase 2:8
Phase 3:12
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (96 trials with phase data)• Click on a phase to view related trials
Phase 1
74 (77.1%)Phase 3
12 (12.5%)Phase 2
8 (8.3%)Not Applicable
2 (2.1%)A Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants With Homologous Recombination-Deficient Stage III/IV Ovarian Cancer (COHORT-C)
Phase 2
Terminated
- Conditions
- Ovarian Neoplasms
- Interventions
- First Posted Date
- 2025-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT06964165
- Locations
- 🇪🇸
GSK Investigational Site, Pamplona, ES, Spain
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
Phase 2
Completed
- Conditions
- Ovarian Neoplasm
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT05751629
- Locations
- 🇺🇸
GSK Investigational Site, Oklahoma City, Oklahoma, United States
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Phase 3
Active, not recruiting
- Conditions
- Neoplasms
- Interventions
- Drug: Placebo matching dostarlimab
- First Posted Date
- 2019-06-11
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 785
- Registration Number
- NCT03981796
- Locations
- 🇬🇧
GSK Investigational Site, Truro, United Kingdom
Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer
- First Posted Date
- 2019-05-20
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT03955471
- Locations
- 🇺🇸
GSK Investigational Site, Charlottesville, Virginia, United States
A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer
Phase 3
Active, not recruiting
- Conditions
- Ovarian, Fallopian Tube and Primary Peritoneal CarcinomaOvarian Neoplasms
- Interventions
- Drug: Standard of careDrug: Dostarlimab-PlaceboDrug: Niraparib-Placebo
- First Posted Date
- 2018-07-27
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Tesaro, Inc.
- Target Recruit Count
- 1402
- Registration Number
- NCT03602859
- Locations
- 🇬🇧
GSK Investigational Site, Wirral, United Kingdom
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
No news found